ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update

Rhea-AI Summary

ReShape Lifesciences Inc. will report its financial results for Q3 2023 on November 8, 2023. The company will also provide a corporate update. A conference call will be held at 5:00 pm ET on November 8, with a live webcast available on the company's website. Participants can access the call by phone and an archived replay will be available on the website.

Conference Call to be Held at 5:00 pm ET on Wednesday, November 8, 2023

IRVINE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the third quarter ended September 30, 2023, including a corporate update on Wednesday, November 8, 2023, after market.

Management will host a conference call on November 8 at 5:00 pm ET. A live webcast will be available on the “Events and Presentations” section of ReShape’s website at: https://ir.reshapelifesciences.com/events-and-presentations.

To access the call by phone, please register with the following Registration Link, and dial-in details will be provided. Participants using this feature are requested to dial into the conference call fifteen minutes ahead of time to avoid delays. An archived replay will also be available on the “Events and Presentations” section of ReShape’s website at: https://ir.reshapelifesciences.com/events-and-presentations.

About ReShape Lifesciences®
ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.

CONTACTS:
Company Contact:                                       
Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com                                       

Investor Relations Contact:
Rx Communications Group
Michael Miller
(917)-633-6086
mmiller@rxir.com

 

FAQ

When will ReShape Lifesciences Inc. report its financial results for Q3 2023?

ReShape Lifesciences Inc. will report its financial results for the third quarter ended September 30, 2023, on Wednesday, November 8, 2023.

What will be included in the corporate update?

The corporate update will provide information about ReShape Lifesciences Inc.'s latest developments and progress.

When is the conference call scheduled?

The conference call is scheduled for Wednesday, November 8, 2023, at 5:00 pm ET.

How can participants access the conference call?

Participants can access the conference call by phone. Registration is required, and dial-in details will be provided.

Where can the live webcast of the conference call be found?

The live webcast of the conference call can be found on the 'Events and Presentations' section of ReShape Lifesciences Inc.'s website.

Will there be an archived replay of the conference call?

Yes, an archived replay of the conference call will be available on the 'Events and Presentations' section of ReShape Lifesciences Inc.'s website.